Movement Disorders

ACI-12589 aims to become the world’s first diagnostic tool for assessing brain alpha-synuclein pathology in patients with Parkinson disease.

The chief scientific officer of the Parkinson’s Foundation discussed the state of mental health services for people with Parkinson disease during the COVID-19 pandemic.

AMT-130 is uniQure’s first clinical program focusing on the central nervous system incorporating its proprietary miQURE silencing technology platform.

Neurology News Network for the week ending February 13, 2021.

Both therapeutic programs utilize AAD2-GDNF gene therapy targeted to brain structures vulnerable to Parkinson disease and multiple system atrophy.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 12, 2021.

The treatment can be used in children who do not respond well to anticholinergic medications.

Data from a small study showed patients experienced significant improvements in MDS-UPDRS III scores after 4 months of treatment with single-hemisphere FUS.

Here's what is coming soon to NeurologyLive.

The chief medical officer at SanBio discussed how the investigational agent SB623 is being studied in TBI and stroke, with future planned studies in Alzheimer disease.

The director of the Parkinson’s Disease and Movement Disorder Program at Emory University School of Medicine shared his perspective on the research and development of Parkinson therapies.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 5, 2021.

The chief scientific officer of the Parkinson’s Foundation discussed strategies to close the gap between household income and telehealth use.

Gocovri is now the only therapy to be approved in the US to treat both off episodes and dyskinesia in patients with Parkinson disease.

Neurocrine Biosciences and Voyager Therapeutics have terminated the Parkinson disease portion of their partnership, ending development for VY-AADC, also known as NBIb-1817.

The director of the Parkinson’s Disease and Movement Disorder Program at Emory University School of Medicine explained the various factors that make Parkinson so difficult to manage.

Here's what is coming soon to NeurologyLive.

The study also found that patients with PD that used telehealth for mental health services were less likely to prefer telehealth over in-office visits.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 29, 2021.

If approved, adaptive DBS could be added to Medtronic’s Percept device, which was approved in June 2020.

Rafael Carbunaru, PhD, MSc, vice president, research and development, Neuromodulation, Boston Scientific, discussed the system’s recent FDA approval.

Here's what is coming soon to NeurologyLive.

Patients with SCD and schizophrenia specifically had increased risk of developing Parkinson disease later in life.

The chief medical officer at SanBio discussed how the investigational agent SB623 can fill the void of disease-modifying therapies for TBI.

Olfactory impairment is indicative of rapid eye movement sleep behavior disorder, a prodromal symptom of Parkinson disease.